Understanding how GIP affects blood flow and metabolism after eating in people with type 2 diabetes
The Role of GIP in Postprandial Splanchnic Blood Flow Distribution and Metabolism in Patients With Type 2 Diabetes
This study is testing how a gut hormone called GIP affects blood flow and metabolism after eating in people with type 2 diabetes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 20 Years to 80 Years |
| Sex | All |
| Sponsor | University of Copenhagen Academic / other |
| Locations | 1 site (Copenhagen) |
| Trial ID | NCT06426823 on ClinicalTrials.gov |
What this trial studies
This project investigates the role of the gut hormone GIP in regulating blood flow and metabolism following glucose ingestion in individuals with type 2 diabetes. Participants will undergo four separate experimental sessions involving MRI scans, where they will receive either a saline solution or a GIP receptor antagonist alongside an oral glucose tolerance test. The study aims to elucidate the mechanisms by which GIP influences gastrointestinal blood flow and metabolic responses. Blood samples will also be collected to analyze hormonal responses from various organs involved in metabolism.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals aged 20-80 with type 2 diabetes and a BMI between 20-35 kg/m².
Not a fit: Patients with conditions affecting kidney or liver function, or those with MRI incompatibilities, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of blood flow and metabolic responses in patients with type 2 diabetes.
How similar studies have performed: While the specific approach of this study may be novel, similar studies investigating gut hormones and metabolic responses have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Type 2 diabetes * BMI 20-35 kg/m\^2 * Age 20-80 Exclusion Criteria: * Not MRI-compatible implants * Claustrophobia * Abnormal kidney or liver function * Anemia * Planned weight loss or change in diet * Hypertension * Other conditions that could be expected to affect the primary or secondary outcomes
Where this trial is running
Copenhagen
- Rigshospitalet — Copenhagen, Denmark (Recruiting)
Study contacts
- Study coordinator: Lærke S Gasbjerg, MD PhD
- Email: lsg@sund.ku.dk
- Phone: 25346894
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.